spec sheet8 rows
TAK-418; a brain-penetrant LSD1/KDM1A epigenetic inhibitor for neurodevelopmental disorders that re-normalizes dysregulated gene expression while sparing the blood toxicity of earlier LSD1 drugs; clean phase 1, efficacy unproven.
- novel epigenetic mechanism: inhibits LSD1 to raise H3K4 methylation and re-normalize dysregulated brain gene expression
- almost fully normalized aberrant gene expression and improved autism-like deficits in neurodevelopmental-disorder models
- specifically engineered to avoid the hematologic toxicity (thrombocytopenia) of earlier LSD1 inhibitors
- brain-penetrant, well tolerated in phase 1 with near-linear pharmacokinetics
Overview
a brain-penetrant LSD1 (KDM1A) inhibitor for neurodevelopmental disorders like Kabuki syndrome; it re-normalizes dysregulated gene expression at the epigenetic level and was engineered to skip the blood toxicity of older LSD1 drugs. clean phase 1, efficacy still unproven.
- it does not touch any neurotransmitter receptor; it works on the epigenetic machinery that decides which genes are on.
- older drugs like it (built for cancer) wreck platelet counts; TAK-418 was redesigned specifically to avoid that.
- in animal models it almost completely reset abnormal brain gene expression, not just a handful of genes.
- it was aimed at Kabuki syndrome, a disorder caused by broken histone-methylation genes.
Mechanism
TAK-418 is a selective, brain-penetrant inhibitor of lysine-specific demethylase 1A (LSD1, also KDM1A), an epigenetic enzyme that demethylates methylated histone H3 lysine 4 (H3K4). by inhibiting LSD1's enzymatic activity, TAK-418 increases H3K4 methylation and thereby shifts the transcriptional program of neurons, an approach aimed at diseases where persistent epigenetic dysregulation underlies the pathology. according to PubMed, in rodent models where maternal valproate or poly(I:C) exposure caused sustained dysregulation of brain gene expression and autism-like social and cognitive deficits, TAK-418 almost completely normalized the dysregulated gene expression and ameliorated the behavioral deficits, and it did so by acting on the aberrant epigenetic machinery rather than a fixed set of genes (the specific genes it corrected differed across models and ages) (Baba et al., 2021, Sci Adv, https://doi.org/10.1126/sciadv.aba1187). the headline therapeutic target is neurodevelopmental disorders such as Kabuki syndrome, an intellectual-disability disorder caused by mutations in histone-methylation machinery, where boosting methylation is mechanistically rational. a crucial part of TAK-418's story is safety engineering: earlier LSD1 inhibitors, largely developed for hematologic cancers, cause thrombocytopenia and other blood toxicities by disrupting LSD1's interaction with cofactors like GFI1B.
Takeda's medicinal chemistry deliberately designed TAK-418 to inhibit the enzyme without inducing GFI1B dissociation (using GFI1 mRNA induction as an in vitro surrogate), yielding a compound with a hematologic safety profile in rodents and humans that older inhibitors lacked (Hattori et al., 2022, Eur J Med Chem, https://doi.org/10.1016/j.ejmech.2022.114522). two phase 1 studies in healthy volunteers confirmed it was well tolerated with no serious adverse events, had near-linear pharmacokinetics, crossed the rapidly, and produced a dose-dependent peripheral pharmacodynamic biomarker response (Yin et al., 2021, Br J Clin Pharmacol, https://doi.org/10.1111/bcp.14912). the honest status: a mechanistically novel, brain-penetrant epigenetic drug with compelling preclinical normalization of gene expression and behavior, and a clean phase 1, but no proven clinical efficacy yet.
receptor fingerprint
Lysine-specific demethylase 1A (LSD1 / KDM1A)selective inhibitor of LSD1 enzyme activity; increases methylation of histone H3 lysine 4 (H3K4)
LSD1-GFI1B cofactor interaction (spared)designed NOT to disrupt LSD1-GFI1B binding, avoiding the hematologic toxicity of earlier LSD1 inhibitors
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
TAK-418 was well tolerated in phase 1 healthy-volunteer studies, with no serious adverse events reported and, by design, a much lower hematologic-toxicity risk than earlier LSD1 inhibitors (it spares the LSD1-GFI1B interaction that drives thrombocytopenia). still, it modulates epigenetic machinery, so long-term and disease-population safety remain to be established. it is an investigational drug with no approved indication and no consumer dose; it is not something to self-administer, and any grey-market sourcing is unverified.
History
TAK-418 emerged from Takeda's effort to repurpose LSD1 inhibition, previously an oncology strategy, for central nervous system neurodevelopmental disorders, targeting the epigenetic dysregulation seen in conditions like Kabuki syndrome. the medicinal-chemistry program was defined by solving the hematologic-toxicity problem of prior LSD1 inhibitors, arriving at a compound that inhibits the enzyme without disrupting GFI1B. after preclinical normalization of gene expression and behavior (2021) and two clean phase 1 studies, it stood as a proof-of-concept for brain-directed epigenetic therapy.
Reputation
in the epigenetics and neurodevelopmental-disorder communities TAK-418 is viewed as a landmark tool compound: one of the first brain-penetrant LSD1 inhibitors deliberately built to be safe on blood counts, and a real demonstration that an epigenetic enzyme can be drugged for CNS indications. it is respected for its novelty and clean phase 1, tempered by the fact that clinical efficacy in the target disorders is unproven.
Subjective profileweighing the evidence above
Well designed and worth following. Engineering out the thrombocytopenia that sank earlier LSD1 inhibitors is not a small achievement, and phase 1 was clean with near-linear pharmacokinetics. Efficacy in people is entirely unproven, there is no dose and no legitimate supply, and epigenetic machinery is the last thing anyone should experiment on privately.
Resources
This entry is here for reference.
Research
- 1.LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models
- 2.Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A
- 3.Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects.
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is TAK-418?
it is a brain-penetrant inhibitor of LSD1 (also called KDM1A), an enzyme that removes methyl marks from histones and so shapes which genes are switched on. by blocking LSD1's enzymatic activity, TAK-418 raises H3K4 methylation and can re-normalize gene expression that has gone awry in certain neurodevelopmental disorders (Baba et al., 2021, Sci Adv, https://doi.org/10.1126/sciadv.aba1187).
what is it being developed for?
central nervous system neurodevelopmental disorders driven by epigenetic dysregulation, most specifically Kabuki syndrome (an intellectual-disability disorder caused by histone-methylation gene mutations) and autism-spectrum-disorder models. the hypothesis is that restoring histone methylation balance could improve cognition and social behavior (Yin et al., 2021, Br J Clin Pharmacol, https://doi.org/10.1111/bcp.14912).
does it work?
in animal models, it is striking. in valproate- and poly(I:C)-exposure models of neurodevelopmental disorder, TAK-418 almost completely normalized the dysregulated brain gene expression and improved autism-like social and cognitive deficits (Baba et al., 2021, Sci Adv, https://doi.org/10.1126/sciadv.aba1187). human efficacy has not yet been demonstrated; it has completed phase 1 safety studies.
is inhibiting an epigenetic enzyme safe?
that was the central design problem. most LSD1 inhibitors (developed for cancer) cause hematologic toxicity like thrombocytopenia because they disrupt LSD1's interaction with the cofactor GFI1B. TAK-418 was specifically engineered NOT to trigger that GFI1B dissociation, giving it a much better blood-safety profile in rodents and humans (Hattori et al., 2022, Eur J Med Chem, https://doi.org/10.1016/j.ejmech.2022.114522).
was it tested in people?
yes, for safety. two phase 1 studies (single- and multiple-rising-dose) in healthy volunteers found TAK-418 well tolerated with no serious adverse events, near-linear pharmacokinetics, rapid brain penetration, and a dose-dependent peripheral pharmacodynamic biomarker response (Yin et al., 2021, Br J Clin Pharmacol, https://doi.org/10.1111/bcp.14912; NCT03228433, NCT03501069). that supports further study but does not yet prove clinical benefit.
how is this different from most brain drugs?
it does not target a neurotransmitter receptor or transporter at all. it works upstream, at the level of the epigenetic machinery that decides which genes are expressed, aiming to restore a healthy gene-expression pattern rather than tweak a single signaling pathway. that is a genuinely different, and still largely experimental, way to approach brain disorders.
can i take it as a nootropic?
no. it is an investigational epigenetic drug for specific neurodevelopmental disorders, with no approved use and no consumer dose. modulating epigenetic enzymes is not something to self-experiment with; it is included here to document a novel mechanism, not to recommend it.